Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Conditions
Interventions
Intervention1: Indomethacin: Drug dose - Capsule (C) - 75 mg sustained release
formulation once daily for 7 days for subjects with
BMI less than 30
C. 75 mg twice daily for 5 days for
subjects with BMI more than 30 will be administered
orally, along with standard care of treatment followed in the hospital
Control Intervention1: Paracetamol: Table
Sponsors
IIT Madras
Eligibility
Inclusion criteria
Inclusion criteria: Age between 20 to 90 years RT â?? PCR Positive Hospitalised patients dyspnea A blood oxygen saturation of 93% or less A ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen (Pao2:Fio2) of less than 300 mm Hg, or infiltrates in more than 50% of the lung field
Exclusion criteria
Exclusion criteria: Hypersensitivity/Allergy to Drug Gastritis Recent Heart attack Severe Asthma Acute Kidney Injury Patients with known history of Indomethacin allergy will be excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in Covid-19 symptoms and the intervention is expected to be beneficial in reducing the Covid 19 symptoms than the comparatorTimepoint: Day 0 screening Day 1 to 7 drug Day 28 end of the study | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety both the intervention and comparator are routinely used drugs and are expected to be safe with no adverse effectsTimepoint: Day 0 screening Day 1 to 7 drug Day 28 end of the study | — |
Countries
India
Contacts
Public ContactDr Ramarathnam Krishna Kumar
MIOT International
Outcome results
None listed